Newamsterdam Pharma Co. NV-27NAMSWPreferred / convertible
13F holders, Q2 2025 (June 30)10holders
0new positions
0sold out
$8.00avg. 13F price*
At the end of Q2 2025, 10 institutions reported holding Newamsterdam Pharma Co. NV-27 (NAMSW) in their 13F filings, unchanged from Q1 2025. 0 opened new positions and 0 sold out. The largest holders were Frazier Life Sciences Management, L.P. ($4.0M), Ra Capital Management, L.P. ($2.7M) and Affinity Asset Advisors, LLC ($2.0M).
- Company
- Newamsterdam Pharma Co. NV-27
- CUSIP
- N62509117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 5,043 shares bought and 8,181 shares sold, net −3,138 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Frazier Life Sciences Management, L.P. | — | No change | 500,333 | $4.0M |
| Ra Capital Management, L.P. | — | No change | 333,333 | $2.7M |
| Affinity Asset Advisors, LLC | — | Add +1.3% | 245,000 | $2.0M |
| Bain Capital Life Sciences Investors, LLC | — | No change | 100,000 | $800K |
| Deerfield Management Company, L.P. | — | No change | 92,787 | $742K |
| Laurion Capital Management LP | — | No change | 16,666 | $133K |
| Vestcor Inc | — | No change | 9,632 | $77K |
| CIBC Private Wealth Group LLC | — | Add +200.0% | 3,000 | $24K |
| Wolverine Asset Management LLC | — | Reduce -76.5% | 2,091 | $17K |
| UBS Group AG | — | Reduce -58.3% | 993 | $8K |
"% of holder's portfolio" is NAMSW's weight in each manager's 13F, not the share of Newamsterdam Pharma Co. NV-27 the manager owns.